Esperion Therapeutics ESPR Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's operating lease right-of-use assets in other assets?
- Esperion Therapeutics (ESPR) reported operating lease right-of-use assets in other assets of $2.7M in Q1 2026.
- How has Esperion Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- Esperion Therapeutics's operating lease right-of-use assets in other assets decreased by 45.6% year-over-year, from $4.97M to $2.7M.
- What is the long-term trend for Esperion Therapeutics's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Esperion Therapeutics's operating lease right-of-use assets in other assets has grown at a -13.5% compound annual growth rate (CAGR), from $6.03M to $2.92M.